BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether metastases are representative of their primary in terms of VEGF expression, hyp...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.
If you are the owner of this record, you can report an update to it here: Report update to this record